Asset
INFIGRATINIB
BridgeBio Pharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02150967 | phase2 | terminated | 2014-07-23 | 2021-03-01 | QED Therapeutics, a BridgeBio company | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma |
| NCT03773302 | phase3 | terminated | 2019-12-27 | 2023-03-02 | QED Therapeutics, a BridgeBio company | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations |
FDA applications (0)
This company has no applications containing this asset.